{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":4,"x_thread":3,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02143466\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT02143466","nct_id":"NCT02143466","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02143466. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"AZD9291 in combination with AZD6094","label":"AZD6094","type":"EXPERIMENTAL"},{"description":"AZD9291 in combination with selumetinib","label":"Selumetinib","type":"EXPERIMENTAL"},{"description":"AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.","label":"MEDI4736","type":"EXPERIMENTAL"},{"description":"AZD6094 in monotherapy (for Japan only)","label":"AZD6094 (monotherapy)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Advanced Non Small Cell Lung Cancer"],"enrollment":{"count":344,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Part A - AZD9291 in combination with AZD6094","type":"DRUG"},{"name":"Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)","type":"DRUG"},{"name":"Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)","type":"DRUG"},{"name":"Part A - AZD9291 in combination with intermittent selumetinib","type":"DRUG"},{"name":"Part A - AZD9291 in combination with MEDI4736","type":"DRUG"},{"name":"Part B - AZD9291 in combination with AZD6094","type":"DRUG"},{"name":"Part B - AZD9291 in combination with selumetinib","type":"DRUG"},{"name":"Part B - AZD9291 in combination with MEDI4736","type":"DRUG"},{"name":"Part C - AZD6094 monotherapy (Japan only)","type":"DRUG"},{"name":"Part C - AZD9291 in combination with AZD6094 (Japan only)","type":"DRUG"},{"name":"Part D - AZD9291 in combination with AZD6094","type":"DRUG"}],"last_update":"2026-07-20","lead_sponsor":"AstraZeneca","official_title":"A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2020-03-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinib","timeFrame":"Adverse events will be collected from baseline until 28 days after the last dose in the AZD6094 or selumetinib arms."},{"measure":"Number of participants with Adverse Events as a measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinib","timeFrame":"Adverse events: baseline until 28 days after the last dose in the AZD6094 or selumetinib arms."}],"references":[{"citation":"Ahn MJ, Cho BC, Ou X, Walding A, Dymond AW, Ren S, Cantarini M, Janne PA. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. J Thorac Oncol. 2022 May;17(5):718-723. doi: 10.1016/j.jtho.2022.01.012. Epub 2022 Feb 15.","pmid":"35181499","type":"DERIVED"},{"citation":"Yoh K, Hirashima T, Saka H, Kurata T, Ohe Y, Hida T, Mellemgaard A, Verheijen RB, Ou X, Ahmed GF, Hayama M, Sugibayashi K, Oxnard GR. Savolitinib +/- Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Target Oncol. 2021 May;16(3):339-355. doi: 10.1007/s11523-021-00806-5. Epub 2021 May 3.","pmid":"33939068","type":"DERIVED"},{"citation":"Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24.","pmid":"32139298","type":"DERIVED"},{"citation":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3.","pmid":"32027846","type":"DERIVED"}],"start_date":{"date":"2014-08-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","url":"https://clinicaltrials.gov/study/NCT02143466"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02143466"}